Reviva Pharmaceuticals (RVPH) investor relations material

Key study updates and milestones

• Brilaroxazine is the lead candidate in phase III, with a second registrational trial planned for schizophrenia.

• A recent $10 million raise brings cash reserves to $23 million, extending runway into Q1 2027.

• Major upcoming milestone is FDA feedback on switching the drug product, expected mid-year, which could impact commercial exclusivity and value.

• Patent extension efforts could push exclusivity to 2046, enhancing attractiveness for partnerships and broader indications.

• Preparatory work for the phase III RECOVER-2 trial is complete, pending FDA alignment.

Patent strategy and regulatory considerations

• Patent life for the current formulation is limited, but switching the drug product and new formulation could extend exclusivity to 2046.

• Extending patent life is crucial for expanding into additional indications like bipolar and major depressive disorder.

• The company has filed for the new patent and is expediting approval, with confidence in the process based on industry precedents.

• FDA feedback on the formulation switch is expected within 45–60 days after the meeting.

• Bioequivalence studies are planned and can be completed quickly, minimizing impact on trial timelines.

Clinical trial design and timelines

• RECOVER-2 will mirror RECOVER-1, using global sites and a similar protocol, with 400 patients and 28-day dosing.

• Enrollment is expected to start in Q3 this year, with completion in about 12 months and top-line data by late 2025 or early 2026.

• Minimal competition for patient enrollment is anticipated, supporting rapid trial execution.

• Bioequivalence study in healthy volunteers will take 4–6 weeks and is already being prepared.

• FDA may require this study before phase III, but it is not expected to delay the overall timeline.